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Abstract
Background: At primary care facilities in Nigeria, national treatment guidelines state that malaria should be
symptomatically diagnosed and treated with artemisinin-based combination therapy (ACT). Evidence from
households and health care providers indicates that many patients do not receive the recommended treatment.
This study sought to determine the extent of the problem by collecting data as patients and caregivers leave
health facilities, and determine what influences the treatment received.
Methods: A cross-sectional cluster survey of 2,039 respondents exiting public health centres, pharmacies and
patent medicine dealers was undertaken in urban and rural settings in Enugu State, south-eastern Nigeria.
Results: Although 79% of febrile patients received an anti-malarial, only 23% received an ACT. Many patients (38%)
received sulphadoxine-pyrimethamine (SP). A further 13% of patients received an artemisinin-derivative as a
monotherapy. An estimated 66% of ACT dispensed was in the correct dose. The odds of a patient receiving an
ACT was highly associated with consumer demand (OR: 55.5, p < 0.001).
Conclusion: Few febrile patients attending public health facilities, pharmacies and patent medicine dealers
received an ACT, and the use of artemisinin-monotherapy and less effective anti-malarials is concerning. The results
emphasize the importance of addressing both demand and supply-side influences on malaria treatment and the
need for interventions that target consumer preferences as well as seek to improve health service provision.
Background
Malaria remains a major cause of death and illness in
children and adults in tropical settings. An integrated
strategy is recommended which ensures access to treat-
ment with effective anti-malarials, while also undertak-
ing preventative measures that target vector control [1].
ACT became the recommended treatment for uncom-
plicated malaria, as resistance emerged to conventional
monotherapies, including sulphadoxine-pyrimethamine
(SP), chloroquine and amodiaquine, thereby reducing
their therapeutic efficacy. Over the last decade, countries
have revised their national malaria treatment policies to
adopt ACT as the first-line recommended treatment for
uncomplicated malaria. Although these policies are now
well established, there are persistent problems with their
implementation.
Evidence from several settings on malaria case man-
agement report problems with the choice of treatment,
showing that ACT is often underused and many patients
continue to receive less effective anti-malarials, such as
SP [2-4]. There are also concerns about the availability
and use of artemisinin monotherapy, as drug resistance
is more likely to develop if artemisinin derivatives are
taken without a partner drug [5,6]. Problems with the
dispensing of malaria treatment have also been
observed, with patients frequently receiving inadequate
doses and without advice on how the medicines should
be taken [2,7]. Ensuring accuracy of drug dispensing is
particularly challenging for pharmacies and other drug
retailers which typically stock a multitude of different
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types of ACT and the accurate dosage depends not only
on the patient’s age or weight but varies by brand
depending on the formulation and composition of the
active ingredients [8,9].
In Nigeria, it is estimated that children under five
years of age have between two and four episodes of
malaria each year, and ensuring prompt access to effec-
tive treatment is a key strategy of the Nigerian Federal
Ministry of Health [10]. At the level of primary care, the
national malaria treatment guidelines state that diagno-
sis should be based on symptoms using the Integrated
Management of Childhood Illnesses (IMCI) classification
[10]. Thus, patients presenting with febrile illness at
health facilities without diagnostic testing available
should be presumptively treated for malaria. ACT
became the recommended treatment for uncomplicated
malaria in 2005 and at this time new treatment guide-
lines and training materials were developed [10-12]. The
first-line recommended treatment is artemether-lume-
fantrine (AL), though treatment with artesunate-amodia-
quine (ASAQ), artesunate-mefloquine (ASMQ) and
dihydroartemisinin-piperaquine (DHAPQ) are also con-
sidered acceptable [12]. The policy is also clear that SP
is reserved for intermittent preventive treatment in
pregnancy, and cases of severe malaria should be treated
using quinine injection, artemether injection, or artesu-
nate (either as an injection or suppository); otherwise
the use of monotherapies is no longer recommended.
The provision and utilization of malaria treatment in
south-eastern Nigeria is well researched, with evidence
from household surveys, patient records and from health
care providers at a range of health facilities showing that
many febrile patients do not receive the recommended
anti-malarial [4,13-16]. Much less is known about the
quality of care provided at health facilities, and this
study explores these concerns directly by collecting data
from patients exiting public health facilities and medi-
cine retailers. These types of facilities are the main pro-
viders of malaria treatment at the primary care level
[14]. This paper describes the characteristics of patients
and the health facilities they attend, and their experience
of care, including the nature of the consultation, the
provision of anti-malarial treatments and the quality of
drug dispensing. The paper also investigates whether
patient, health worker or facility factors are associated
with receiving ACT.
Methods
Study area
The study was undertaken in two study sites in Enugu
State in south-eastern Nigeria: Enugu urban (comprising
of Enugu East, Enugu South and Enugu North local gov-
ernment areas (LGAs)) and Udi LGA. Enugu urban is
the largest predominantly urban area in Enugu State,
and Udi LGA is rural. Malaria is endemic in Enugu
State, and occurs all year round. The people of Enugu
are of Igbo ethnicity and speak the Igbo language. The
activities of the majority of the population include farm-
ing, fishing, wine tapping, and poultry keeping and rear-
ing of domestic animals; the main agriculture season
runs from November to February.
ACT was introduced into the study site in 2005 by the
State Malaria Control Programme. The implementation
package consisted of training health workers on sympto-
matic diagnosis, change in antimalarial policy and
rational prescription of antimalarials and was accompa-
nied by a community awareness campaign.
Study setting
The study was undertaken at public primary health
facilities, private sector pharmacies and patent medicine
dealers (PMDs) in Enugu State, south-eastern Nigeria
[17]. The term PMD refers to retail outlets that are
licensed to sell over the counter pharmaceutical pro-
ducts, though often hold a wider range of stock, and
typically have no formal training [18]. Pharmacies and
PMDs are a major source of malaria treatment [14,19].
These facilities are medicine retailers and do not routi-
nely offer clinical care or diagnostic services. At the pri-
mary care level, presumptive treatment of malaria is
recommended in febrile patients, as few public facilities
offer malaria microscopy or RDTs. Primary health cen-
tres are usually staffed by community health officers and
community health extension workers and supported by
registered nurses and midwives [20].
Study design
A stratified multistage cluster survey was conducted
between July and December 2009. The survey sampling
was clustered in 16 randomly selected communities and
stratified by type of facility: i) public facilities including
primary health centres, dispensaries and health posts,
and ii) pharmacies and PMDs. Within each community
all public primary health centres were included due to
their small number. There are a large number of phar-
macies and PMDs, and these were randomly selected
with probability proportionate to size assuming that a
total of 80 (out of 298) medicine retailers could be vis-
ited given the financial resources and time available. All
health workers within each facility responsible for pre-
scribing or dispensing medicines were included in the
study.
A survey sample of 20 patients per public facility was
calculated to estimate the primary outcome, the propor-
tion of febrile patients receiving the recommended treat-
ment for malaria, with a precision of +/- 13%, assuming
that the variability (intra-cluster correlation, ICC) in
treatment between facilities is 0.3 [21]. For pharmacies
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and PMDs, 14 patients per facility allows the primary
outcome to be calculated with a precision of +/- 6.6%
assuming the same degree of variation. The estimates
assume a prevalence of 50% for the primary outcome
and give the maximum range for precision (if the
observed prevalence by higher or lower than 50% then
greater precision would be achieved). The sampling was
based on an enumeration of health facilities and their
staff conducted in April 2009.
Survey activities
In advance of the survey a field team visited each facility
to explain the purpose of the survey to the head of the
facility and obtain informed written consent. Informed
consent was reconfirmed verbally on the day of the
actual survey. The survey questionnaires were developed
specifically for the study and pretested on a non-random
sample of individuals with characteristics similar to
those of the survey population but not chosen for inclu-
sion in the survey. Survey teams were trained on proce-
dures for conducting the survey and involved in the
pretesting and revision of the questionnaires. Site super-
visors monitored and supervised all aspects of data
collection.
Data were collected using three structured approaches;
a patient exit questionnaire, a health worker survey and
a health facility audit. Written consent from patients
and caregivers (who may or may not be accompanied by
the patient) exiting the health facility was sought before
screening to determine their eligibility to participate in
the survey. An individual was considered eligible if s/he
reported seeking treatment for a fever or if s/he had
received an ACT. Treatment may be sought for them-
selves, a child or another person who is not present (the
latter applies only at medicine retailers). Individuals that
were exiting a health facility were assessed in turn until
the patient quota was reached. All workers that were
involved in prescribing or dispensing malaria treatment
and were available at the time of the survey were invited
to complete the health worker survey and written con-
sent was obtained from all participants.
The patient exit questionnaire collected data on the
patient’s prior treatment seeking and use of anti-malar-
ials, reasons for attendance, the consultation and diagno-
sis, prescriptions and medicines received, the cost of
treatment seeking and the demographic characteristics of
the patient. The health worker questionnaire captured
data on their characteristics, access to in-service training
and national malaria treatment guidelines, malaria
knowledge and treatment practices. The health worker
survey was conducted once all the patient exit question-
naires had been completed to ensure that the treatment
received by patients was not influenced by the content of
the health worker questionnaire and the patient exit data
best reflects current prescribing practices. The health
facility audit was conducted following the health worker
survey and collected data on the characteristics of the
health facility, diagnostic services, management and pro-
curement of medicine, including the availability of ACT.
Definitions
The treatment received by patients was assessed against
the national malaria treatment guidelines, which recom-
mends that patients with a fever are presumptively trea-
ted with an ACT, with the exception of pregnant
women in the first trimester. The accuracy of the ACT
dose provided to patients was assessed in accordance
with dosage recommendations based on the patient’s
age and the type and composition of ACT received.
Thus, the analysis takes into account that the correct
number of tablets (or powder sachets) varies by brand,
the amount of active ingredients contained in each
tablet and whether they are co-formulated or co-blis-
tered. Suspensions were excluded from the analysis on
dosing. As patient age was used as a proxy for weight
[11,22] this may cause some error in estimating the
accuracy of dosing among children, though this would
not apply to adults. Patient knowledge on the dose regi-
men was ascertained by asking the patient or their care-
giver to explain how and when the medicine should be
taken. Knowledge was considered accurate if they
reported the number of tablets (or powder sachets)
which should be taken per day over 3 days that corre-
sponds to the specific brand of ACT received, and the
patient’s age. Suspensions were excluded from the analy-
sis due to the difficulties in accessing the accuracy of the
correct dose.
Statistical analysis
Data were entered and verified using Microsoft Access
2007 (Microsoft Inc., Redmond, Washington) and ana-
lysed using STATA version 11.0 (STATA Corporation,
College Station, Texas) that allows for complex survey
design by identifying different probabilities of selection
(sampling weights), clustering and stratification (applying
the prefix svy) [23]. Thus, all percentages and odds ratios
reported are population-average estimates which have
been adjusted to take into account the stratification, clus-
tering and sampling weights of the study design. The
weights are equal to the inverse probability of being
sampled and took into account the sampling probabilities
at the facility, health worker and patient level. At the
patient level, number of days it took to recruit patients
was used to create a proxy for the volume of patients,
with the less time indicative of a larger facility.
Treatment outcomes by strata were compared using
the Rao and Scott chi-square correction [24]. Survey
logistic regression was used to assess factors associated
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with receiving the recommended treatment. The follow-
ing were investigated for their potential association:
characteristics of the patient and health worker, patient
consultation, and the resources available at the health
facility (all factors are listed in Table six). Factors asso-
ciated with receiving the recommended treatment were
investigated in the multivariable model if the univariable
association was statistically significant at the 10 percent
level, or the odds ratio was less than 0.5 or greater than
1.5. Factors were retained in this multivariable model if
they remained significantly associated at the 10% level
of significance or with an adjusted odds ratio less than
0.5 or greater than 1.5. Models were compared using an
adjusted Wald test. Pregnant women and children under
the age of 6 months were excluded from the analysis
because the national malaria treatment guidelines have
alternative recommendations for these groups.
Ethical approval
Ethical approval for this study was obtained from the
ethics committees of University of Nigeria and London
School of Hygiene and Tropical Medicine.
Results
Patient characteristics
Data were collected from 100 health facilities and the
analysis is based on exit data collected from 1,642 febrile
patients attending public facilities and medicine retailers
and 149 health workers (Figure 1). There was notable
variation in the characteristics of patients attending the
different types of health facility (Table 1). More than
half (57%) of the patients treated at public health facil-
ities were children, while 80% of the cases presenting at
pharmacies and PMDs were adults. Treatment-seeking
also varied by education levels and socioeconomic status
(SES), with respondents surveyed at medicine retailers
more likely to have tertiary education and be of a higher
wealth quintile. At medicine retailers81% of patients
reported it was the first time that they had sought treat-
ment for this illness episode, and 43% had sought treat-
ment on the same or day following the onset of
symptoms. While at public facilities 61% of patients at
public facilities were seeking treatment for the first time
and the time before treatment was much longer, with
only 16% seeking treatment on the same or day
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Figure 1 Study population.
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following the onset of symptoms. When asked about
their choice of health facility, many respondents said
that they had sought treatment at this facility for past
illnesses (54%) and it was convenient (55%). In addition,
patients at public health facilities often mentioned the
lower cost of treatment, while the reputation of the pro-
vider and the availability of drugs were more often cited
at medicine retailers.
Table 1 Patient Characteristics by type of facility*
Public Medicine retailer Total
N = 466 % N = 1176 % N = 1642 % P value
Patient genderi
Male 218 45.4 624 56.4 842 55.5 0.006
Female 242 54.6 536 43.6 778 44.5
Patient age
>15 years (adult) 185 42.8 913 79.6 1098 76.7 <0.001
10-15 years 27 6.6 85 7.3 112 7.3
5-9 years 61 12.6 71 4.6 132 5.3
<5 years 193 38.0 107 8.4 300 10.7
Patient socioeconomic statusii
Poorest quintile 223 46.4 343 15.7 566 18.1 <0.001
Second quintile 97 20.4 219 20.0 316 20.1
Third quintile 55 11.8 219 21.3 274 20.6
Fourth quintile 56 13.5 189 21.2 245 20.6
Richest quintile 35 8.0 206 21.8 241 20.7
Education level of patient (or caregiver)iii
No formal education 25 5.8 41 1.3 66 1.6 <0.001
Primary education 116 28.0 198 12.5 314 13.7
Secondary education 213 46.1 469 39.7 682 40.2
Tertiary education 93 20.0 445 46.6 538 44.5
Was first time sought treatmentiv
Yes 269 61.4 896 81.7 1165 81.1 <0.001
No 196 38.7 273 18.3 469 19.9
Number of days since start of symptomsv
None (same day) 14 3.3 234 22.1 248 20.6 <0.001
1 day 71 12.6 259 21.2 330 20.5
2 days 93 19.3 228 21.2 321 21.1
3-5 days 202 45.4 284 23.5 486 25.3
6+ days 85 19.4 169 12.0 254 12.6
Reasons given for choice of health facilityvi
Convenient 229 49.2 617 55.9 846 55.4 0.284
Used previously 243 48.6 732 54.7 975 54.2 0.346
Good reputation 145 30.1 529 49.6 674 48.1 0.002
Availability of drugs 127 23.3 548 48.7 675 46.7 0.001
Inexpensive 206 46.2 178 13.3 384 15.9 <0.001
Qualification of staff 132 24.7 174 12.9 306 13.9 0.011
i missing 22 responses: 6 from public and 16 from medicine retailer
ii Principal components analysis was undertaken to generate a SES index based on household asset ownership [33]. The SES index was disaggregated into wealth
quintiles.
iii missing 42 responses: 19 from public and 23 from medicine retailer
iv missing 8 responses: 1 from public and 7 from medicine retailer
v missing 3 responses: 1 from public and 2 from medicine retailer
vi more than one reason could be given
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Health facility and health worker characteristics
The provision of basic equipment, such as weighing
scales and thermometers was good in public health facil-
ities, though more mixed in pharmacies and PMDs
(Table 2). Very few health facilities offered malaria
microscopy testing and none of the health facilities sur-
veyed used RDTs. At the time of the survey, all health
facilities reported that they had anti-malarials in stock,
and field staff verified that ACT was in stock in 80% of
health facilities. There was some variation by facility
type, with 71% of public health centres and 89% of phar-
macies and PMDs stocking at least one ACT. Two-
thirds of health facilities had artemether-lumefantrine
(AL) available, though other types of ACT were com-
mon in medicine retailers. Artemisinin monotherapy
was available in 96% of medicine retailers while the vast
majority (90%) of facilities also had SP as well as other
types of anti-malarials available; these included less
Table 2 Facility Characteristics
Public Medicine
retailer
Total
HEALTH FACILITIES N = 20 % N = 80 % N = 100 % P value
Equipment and services available
Weighing scale† 19 94.1 36 50.0 55 53.1 <0.001
Thermometer 19 94.2 35 46.5 54 49.8 <0.001
Microscopy services† 3 12.8 0 - 3 0.9 <0.001
RDT 0 - 0 - 0 - -
Availability of anti-malarials
Any anti-malarial 20 100.0 80 100.0 100 100.0 -
Artesunate monotherapy 5 24.6 76 96.1 81 91.1 <0.001
Sulphadoxine Pyrimethamine (SP) † 18 89.8 71 89.9 89 89.9 0.982
Chloroquine 14 71.1 77 96.8 91 95.0 <0.001
Quinine 4 20.3 70 89.1 74 84.3 <0.001
Amodiaquine 3 14.4 60 85.3 63 80.3 <0.001
Any type of ACT 14 71.1 66 89.6 80 88.3 <0.001
Artemether Lumefantrine (AL) 12 65.6 64 79.6 66 78.4 <0.001
Artesunate Amodiaquine (ASAQ) 2 8.6 57 78.8 59 73.9 <0.001
Artesunate Mefloquine (ASMQ) 0 - 35 52.9 35 49.2 <0.001
Artesunate Sulphadoxine-Pyrimethamine (ASSP) 0 - 18 28.4 18 26.4 <0.001
Dihydroartemisinin-Piperaquine (DHAPQ) 0 - 55 78.0 55 72.6 <0.001
Median cost of ACT (& IQ range)
Adult dose of any ACT - 600 (350, 750) 600 (350, 750) -
Child dose of any ACT - 350 (260, 600) 350 (250, 600) -
Adult dose of AL - 750 (650, 835) 750 (650, 820) -
Child dose of AL - 650 (580, 750) 650 (520, 700) -
HEALTH WORKERS N = 50 % N = 99 % N = 149 % P value
Doctor 7 14.0 0 9 1.7 <0.001
Nurse or Midwife 7 14.0 7 7.3 14 8.1
Community Health Officer 14 28.0 1 1.3 15 4.5
Community Health Extension Worker 22 44.0 3 4.1 25 8.9
Pharmacist‡ - 3 3.9 3 3.4
PMD or pharmacy attendant‡ - 85 83.4 85 73.5
HW has attended malaria training in past 3 years 13 24.6 31 33.0 44 31.9 0.011
HW has access to malaria treatment guidelines 15 30.9 4 5.2 19 8.5 <0.001
HW accurately reported ACTs are the recommended treatment for uncomplicated
malaria
38 77.2 44 62.2 82 65.4 <0.001
† missing response from one pharmacy
‡ not applicable in public facilities
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effective conventional treatments such as chloroquine
and amodiaquine.
All the public facilities reported that ACT was avail-
able to patients free of charge. In pharmacies and PMDs
the median price of an ACT was 600 Naira for an adult
dose and 350 Naira for a child dose (which is approxi-
mately equivalent to USD $4.00 and USD $2.30). The
median price of AL was higher at 750 Naira for an adult
dose and 650 Naira for a child dose (equivalent to USD
$6.00 and USD $4.30).
Just under half (44%) of workers in public facilities
were community health extension workers, semi-skilled
health workers trained in primary care, and while junior
to the other cadres listed in Table 2 may prescribe treat-
ment or undertake minor procedures [20]. In the medi-
cine retailers the majority (83%) described themselves as
patent medicine dealers or pharmacy attendants.
Knowledge of malaria treatment was variable, though
better in public facilities, as 80% of workers in public
facilities reported that ACT is the recommended treat-
ment for uncomplicated malaria, compared to 62% of
workers in pharmacies and PMDs. Moreover, less than
one in three health workers surveyed had attended an
in-service malaria training workshop over the past three
years and relatively few (9%) had access to the malaria
treatment guidelines (31% of public health workers and
5% of health workers at pharmacies and PMDs).
Patient consultation, prescription and requests for medicine
The nature of the patient’s consultation differed by type
of health facility (Table 3). In public health facilities 95%
of respondents reported the health workers were told of
the patient’s symptoms, and 90% reported that they had
told the health worker about the patient’s fever. Patients
reported to have been physically examined in 65% of
cases, 50% had their temperature taken, though just 6%
of patients were tested for malaria. At public facilities
with microscopy testing available 21% of patients were
tested for malaria. In pharmacies and PMDs patients
were rarely examined (6%) or tested (<1%), though in
32% of cases health workers were told about the
patient’s symptoms and asked further questions.
The majority of patients attending public facilities had
medicines prescribed and in 78% of cases the prescrip-
tion was for an anti-malarial. ACT was prescribed to
34% of patients seeking treatment, though as many
patients were prescribed SP, which is no longer recom-
mended for treating malaria.
At pharmacies and PMDs, 15% of patients had a pre-
scription and patients often asked for a specific medi-
cine. At these facilities, 58% of patients attending asked
for an anti-malarial. Patients often asked for SP (26%),
though also requested ACT (16%) and artemisinin-
monotherapy (12%). Almost all (96%) of those patients
that asked for an anti-malarial also received the medi-
cine they had requested.
Malaria treatment received by patients
Overall, the majority of patients received an anti-malarial,
though ACT was received by only 22% of all patients
attending health facilities and by 29% of children under
five years of age (Table 4). SP is no longer recommended,
though still frequently used, and 38% of patients had
received this medicine. At public facilities, differences
were observed between the proportion of patients that
were prescribed and received antimalarials at facilities
which had ACT in stock. The proportion of patients that
received an antimalarial at public facilities was also low
compared to the medicine retailers. There were, however,
few differences between the proportions of patients
receiving ACT and SP at public health facilities and med-
icine retailers, though patients were more likely to receive
oral artemisinin monotherapy at medicine retailers than
public facilities (14% compared to 2%, p < 0.001). Other
anti-malarials, such as chloroquine, amodiaquine and
quinine were rarely received by patients. By type of ACT,
AL (44%) was most often dispensed and was widely used
in the public sector. In medicine retailers, AL was regu-
larly dispensed, though patients also received ASAQ and
DHAPQ.
Quality of dispensing of ACT
Two-thirds (66%) of all types of ACT dispensed were
estimated to be in the correct dose, while 58% of ACT
dispensed were in the correct dose and the patient (or
their caregiver) accurately reported how the medicine
should be taken (Table 5). Given the challenges in esti-
mating the accuracy of ACT dosage in children, the
results are also presented for febrile adults receiving
ACT. Overall the results are reasonably similar, with
56% of ACT received in the correct dose and by patients
that had accurate knowledge of how to take the medi-
cine. Very few patients receiving an ACT were told of
any side effects associated with the medicine.
Factors influencing treatment received by patients
The odds of a febrile patient receiving an ACT were
significantly associated with whether the patient had a
prescription, asked for an ACT, the patient’s gender,
and the education level of the patient (or their care-
giver) (Table 6). Patients were also significantly more
likely to receive an ACT at health facilities that were
better equipped, and had one or more health workers
that knew ACT was recommended for uncomplicated
malaria. Patients that chose the health facility because
it was convenient or relatively inexpensive were signifi-
cantly less likely to receive an ACT. Of all the vari-
ables considered in the univariable analysis, patients
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asking for ACT had by far the highest odds ratio of
53.3 (15.9-179.1, p < 0.001). This variable remained
highly significant in the multivariable model with an
odds ratio of 55.5 (15.0-205.6, p < 0.001), though the
other significant variables were the patient’s gender,
the education level of the patient (or caregiver),
whether the facility had a thermometer available, and
whether the facility had health workers that knew ACT
was recommended.
Discussion
There is great need to improve the quality of care for
uncomplicated malaria in south-eastern Nigeria. Parasi-
tological diagnosis was available in only 3% of facilities
and while the national malaria treatment guidelines
recommend presumptive treatment of a fever with ACT
when malaria tests are not available, less than a quarter
(22%) of febrile patients attending facilities received the
recommended treatment. Moreover, the estimates show
that only 58% of patients that received ACT were given
the correct dose and knew how the medicine should be
taken. Inadequate dosing and poor compliance to treat-
ment regimens will reduce the efficacy of the treatment
taken and may contribute to the development of drug
resistance [25].
After four years with ACT as the recommended first-
line antimalarial, these results at public health facilities
are extremely concerning. In Kenya and Zambia poor
Table 3 Patient consultation
Public Medicine retailer Total
N = 466 N = 1176 N = 1642
% (95% CI) % (95% CI) % (95% CI) P value
Patient reported consultation
Told HW about patient symptoms 94.9 (94.4-95.4) 44.3 (36.9-52.0) 48.3 (41.3-55.4) <0.001
Told HW that had a fever 89.8 (87.2-91.9) 40.3 (33.0-48.2) 44.3 (37.1-51.4) <0.001
HW asked follow up questions about patient’s symptoms 79.9 (76.3-83.0) 32.0 (25.0-39.9) 35.7 (29.1-43.1) <0.001
Patient was physically examined 65.1 (48.8-78.5) 6.2 (3.5-10.5) 10.8 (7.8-14.5) <0.001
Patient had temperature taken 49.7 (38.6-60.9) 1.7 (0.6-4.9) 5.5 (3.9-7.8) <0.001
Patient tested for malaria at this facility 5.8 (3.6-9.3) 0.2 (0.0-1.4) 0.7 (0.3-1.3) <0.001
Patient requests for medicine
% of patients that asked for:
any type of medicine 2.8 (1.9-4.2) 65.4 (57.9-72.3) 60.5 (53.7-66.9) <0.001
an anti-malarial 1.2 (0.7-2.1) 58.3 (51.1-65.2) 53.8 (47.3-60.2) <0.001
any ACT 0.9 (0.4-1.9) 16.0 (11.1-22.5) 14.8 (10.3-20.9) <0.001
Artemisinin monotherapy 0 11.5 (8.6-15.3) 10.6 (8.0-14.1) 0.162
Amodiaquine 0 1.6 (0.8-3.4) 1.5 (0.7-3.2) 0.402
Chloroquine 0.1 (0.0-0.4) 1.3 (0.6-2.7) 1.2 (0.6-2.5) <0.001
Quinine 0 0.7 (0.2-2.6) 0.7 (0.2-2.4) 0.631
SP 0.1 (0.1-0.1) 26.2 (21.5-31.5) 24.1 (19.8-29.1) <0.001
Anti-malarial prescriptions
% patients prescription (from any facility) 94.2 (92.4-95.6) 15.4 (10.7-21.5) 21.6 (17.1-26.9) <0.001
% patients that received prescription from this facility 94.2 (92.4-95.6) 1.8 (0.7-4.0) 8.8 (7.3-11.0) <0.001
% patients that were prescribed*: - - -
an anti-malarial† 78.4 (72.6-83.3) - - -
any ACT‡ 34.0 (21.9-48.7) - - -
Artemisinin monotherapy 4.7 (3.1-7.1) - - -
Amodiaquine 1.1 (0.9-1.5) - - -
Chloroquine 3.3 (0.8-11.6) - - -
Quinine 0.2 (0.0-3.1) - - -
SP 34.7 (21.7-50.6) - - -
* Reported only for public health facilities
† At public facilities 73.4% of children under five years were prescribed an antimalarial.
‡ At public facilities 51.5% of children under five years were prescribed an ACT. At public health facilities with ACTs in stock 43.8% of patients (all ages) and
57.9% of children under five years were prescribed an ACT.
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quality treatment practices were observed at public and
mission facilities soon after ACT was introduced as
first-line, though subsequent studies up to five years
later show improvements in the proportion of patients
that are prescribed and receive ACT [3,7,26]. As found
elsewhere, the proportion of patients that were pre-
scribed or received an ACT seems low given the avail-
ability of ACT at health facilities and the proportion of
health workers that knew ACT was recommended
[3,7,27,28]. It was also interesting to note that only half
of patients at public facilities that were prescribed an
ACT also received one, though it is not clear why this
occurred: 34% of patients at public facilities were pre-
scribed an ACT, while 17% received an ACT. The dis-
crepancy is only partially explained by the availability of
ACT and is unlikely to reflect the cost of treatment, as
ACT is provided to patients in public facilities without
charge.
There were some problems with the availability of
ACT: 70% of public facilities and 83% of pharmacies
and PMDs had at least one ACT in stock at the time of
the survey. While the availability of ACT in the public
sector was not as high as has been reported in Angola,
Kenya, or Uganda [7,9,28-30], the availability of ACT in
the study sites was much higher than the Nigerian
national average from 2008, when it was found that 38%
of public health facilities had ACT in stock. The avail-
ability of ACT at private sector outlets was found to be
higher than the Nigerian national average from 2008,
which reported 78% of pharmacies and 19% of PMDs
had ACT in stock [9]. It is concerning to find that arte-
misinin monotherapy is widely available in medicine
Table 4 Anti-malarials received
Public Medicine retailer Total
% (95% CI) % (95% CI) % (95% CI) P value
Anti-malarials received (all ages) N = 466 N = 1176 N = 1642
% of patients (of all ages) that received:
an anti-malarial 54.2 (44.1-63.9) 81.5 (76.2-85.8) 79.3 (74.5-83.4) <0.001
any ACT† 17.3 (9.0-30.5) 22.8 (17.2-29.7) 22.4 (17.0-28.8) 0.378
Artemisinin monotherapy* 2.0 (0.8-5.2) 14.4 (11.4-18.0) 13.4 (10.6-16.7) <0.001
Amodiaquine 0.1 (0.00-1.0) 2.0 (0.9-4.6) 1.9 (0.8-4.2) 0.002
Chloroquine 2.4 (0.5-10.6) 3.3 (2.0-5.4) 3.2 (2.0-5.2) 0.673
Quinine 0 0.9 (0.3-2.2) 0.8 (0.3-2.0) 0.501
SP 33.6 (20.9-49.1) 38.2 (31.8-45.1) 37.9 (31.8-44.3) 0.546
Anti-malarials received (children < 5 yrs only) N = 193 N = 107 N = 300
% of children <5 years that received:
an anti-malarial 33.2 (20.0-49.7) 80.2 (63.6-90.4) 67.1 (53.7-78.1) 0.001
any ACT‡ 21.3 (9.9-39.9) 31.6 (18.2-49.0) 28.7 (18.0-42.6) 0.329
Artemisinin monotherapy* 2.0 (0.2-14.5) 10.2 (3.4-26.8) 7.9 (2.9-20.2) 0.110
Amodiaquine 0.2 (0.0-3.0) 9.3 (2.3-30.6) 6.7 (1.6-23.8) 0.001
Chloroquine 1.5 (0.7-3.2) 12.6 (4.2-32.1) 9.5 (3.5-23.5) 0.001
Quinine 0 4.5 (0.6-26.8) 3.23 (0.5-20.2) 0.497
SP 9.2 (3.7-21.0) 19.9 (8.5-40.0) 16.9 (8.1-32.0) 0.176
Type of ACT received N = 105 N = 210 N = 315
% AL 96.5 (92.5-98.4) 40.2 (26.9-55.1) 43.6 (31.0-57.2) <0.001
% ASAQ 3.0 (1.4-6.2) 28.5 (16.1-45.2) 26.9 (15.3-42.8) <0.001
% DHAPQ 0 24.3 (15.1-36.5) 22.8 (14.3-34.3) 0.074
% ASMQ 0.5 (0.1-1.9) 4.1 (0.9-16.6) 3.9 (0.9-15.5) 0.019
% ASSP 0 2.9 (0.7-11.5) 2.8 (0.7-10.8) 0.648
† At facilities with ACTs in stock 27.0% (20.4-34.7%) of patients at public facilities and 24.2% (17.9-31.9%) of patients at medicine retailers received an ACT
‡ At facilities with ACTs in stock 31.7% (22.0-43.4%) of children under five years at public facilities and 32.5% (18.0-51.3%) of children under five years at
medicine retailers received an ACT
* This was in tablet form at medicine retailers.
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retailers and that many patients request this medicine.
The use of oral artemisinin monotherapy in 13.4% of
patients is also a major concern, since its use without a
combination therapy can lead to the development of
drug resistance [5,6].
Differences observed between the characteristics of
patients by type of health facility are broadly consistent
with evidence from household surveys conducted in
Nigeria on malaria treatment seeking. For example,
rural-urban differences, the education of caregivers, and
socioeconomic status have been found to be important
determinants of where treatment is sought
[14,15,31-33]. Other studies have also shown that urban
residents were more likely to obtain ACT [15] and indi-
viduals of higher levels of education and socioeconomic
status were more likely to have correct knowledge of
malaria treatment [31].
Differences between the facility types in the
resources available and the patient’s consultation were
much as expected, with patients attending public
health facilities more likely to discuss symptoms and
be examined. Similarly, as pharmacies and PMDs are
retail outlets it is not surprising that many lacked
weighing scales and thermometers and that patients
often asked for specific medicines. Moreover, it was
expected that health workers in public facilities would
have better access to the malaria treatment guidelines
and be more likely to know that ACT is recommended
for uncomplicated malaria.
The odds of a febrile patient receiving an ACT were
positively associated with the health workers knowledge
of the treatment guidelines, though there is no evidence
of an association between access to treatment guidelines
and attendance at malaria training. It should be noted
that these variables were defined at the facility-level
because in many cases it was not possible to link
patients to the health worker that prescribed or recom-
mended treatment, either because the health worker was
absent at the time of the survey or because several
health workers attended to the patient.
The treatment received by patients from medicine
retailers was often driven by consumer requests for a
specific medicine, and the odds of a febrile patient
receiving an ACT were extremely high if the patient or
their caregiver had asked for one. Previous studies from
Nigeria have also highlighted the importance of patient
demand. For example, Onwujekwe et al reports that
40% of providers across a range of primary health facil-
ities said requests by patients influenced the type of
drug provided [4]. Qualitative research with patent med-
icine dealers undertaken by Okeke et al also highlighted
that patients often ask for specific medicines and the
doses of anti-malarial drugs can be determined by
patient’s ability to pay [18]. Patients’ requests for specific
medicine at medicine retailers were likely to include
cases for which treatment had been prescribed else-
where, though as only 15% of patients had a prescrip-
tion other factors are likely to be relevant and there
Table 5 Quality of dispensing for patients that received an ACT
Public Medicine retailer Total
% (95% CI) % (95% CI) % (95% CI) P value
All febrile patients that received an ACT* N = 100 N = 176 N = 276
% accurate dose† 75.8 (70.6-80.2) 65.5 (50.1-78.1) 66.2 (51.8-78.0) 0.135
% patient has accurate knowledge of treatment regimen‡ i 68.3 (63.7-72.6) 58.5 (41.6-73.6) 59.2 (43.4-73.3) 0.218
% patients with accurate dose and knowledge of treatment regimenii 66.8 (61.3-71.9) 57.2 (40.3-72.5) 57.8 (41.7-72.4) 0.236
% patients that reported were told of side effectsiii 1.5 (1.2-1.9) 3.0 (0.6-14.0) 3.0 (0.6-12.9) 0.357
Febrile adults that received an ACT* N = 21 N = 125 N = 146
% in accurate dose† 72.8 (68.6-76.6) 62.0 (43.5-77.5) 62.2 (44.2-77.4) 0.165
% patient has accurate knowledge of treatment regimen‡ iv 72.8 (68.6-76.6) 55.4 (36.3-73.0) 55.8 (37.1-73.0) 0.051
% patients with accurate dose and knowledge of treatment regimeniv 72.8 (68.6-76.6) 55.4 (36.3-73.0) 55.8 (37.1-73.0) 0.051
% patients that reported were told of side effectsv 6.2 (5.0-7.7) 4.2 (0.8-18.5) 4.2 (0.9-17.8) 0.570
* excludes suspensions and syrups and limited to cases for which have data on dosage
† defined as dose that is consistent guidance on dosage by patient age.
‡ defined as patient reports treatment regimen is consistent with guidance on dosage by patient age
i missing 10 observations (2 from public and 8 from medicine retailers)
ii missing 12 observations (4 from public and 8 from medicine retailers)
iii missing 6 observations (2 from public and 4 from medicine retailers)
iv missing 2 observations (from medicine retailers)
v missing 3 observations (from medicine retailers)
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Table 6 Factors influencing whether a patient received an ACT
Variable Univariable Analysis Multivariable Analysis
n/N % OR 95% CI P value OR 95% CI P value
Study Site Enugu 211/989 22.7 1.71 (0.81-3.61) 0.148
Udi 71/531 14.7 1.0
Patient characteristics
Gender Male 173/795 25.3 1.63 (1.00-2.65) 0.051 1.91 (1.02-3.55) 0.045
Female 109/725 17.2 1.0 1.0
Age Group >15 yrs 157/1023 19.8 1.0 0.336
10-15 yrs 16/104 20.7 1.06 (0.44-2.53)
5-9 yrs 38/124 37.8 2.46 (0.90-6.74)
<5 yrs 71/269 29.0 1.65 (0.88-3.09)
Quintile Richest 57/230 28.8 2.35 (1.12-4.96) 0.201
Fourth 48/217 26.2 2.07 (0.99-4.35)
Third 48/257 18.7 1.34 (0.58-3.12)
Second 61/297 19.8 1.44 (0.64-3.25)
Poorest 68/519 14.6 1.0
Education Level No formal 3/61 2.1 0.09 (0.02-0.31) 0.001 0.13 (0.03-0.50) 0.045
Primary 45/297 19.9 1.0 1.0
Secondary 113/651 19.1 0.95 (0.47-1.95) 0.81 (0.35-1.85)
Tertiary 121/511 25.4 1.37 (0.70-2.70) 0.84 (0.41-1.73)
First-time go for treatment Yes 207/1091 21.5 0.93 (0.50-1.73) 0.811
No 75/429 22.7 1.0
Time before treatment Same day 30/229 15.5 1.0 0.368
1 day 58/302 17.8 1.17 (0.49-2.83)
2 days 60/307 23.0 1.62 (0.78-3.38)
3-5 days 95/446 28.0 2.11 (0.97-4.58)
6+ days 39/236 23.4 1.66 (0.64-4.29)
Consultation with health worker (HW)
HW told of symptoms Yes 170/1030 18.0 0.65 (0.34-1.22) 0.162
No 112/490 25.4 1.0
HW is told of patient’s fever Yes 165/961 19.2 0.76 (0.41-1.43) 0.373
No 117/559 23.8 1.0
HW asks follow up Qs Yes 139/700 23.6 1.33 (0.68-2.61) 0.376
No 143/819 18.5 1.0
Patient is examined Yes 83/370 19.5 0.88 (0.42-1.87) 0.724
No 199/1150 22.0 1.0
Takes patient temperature Yes 53/251 19.1 0.90 (0.44-1.85) 0.755
No 229/1269 21.9 1.0
Patient has a prescription Yes 99/327 42.1 3.51 (1.77-6.95) 0.001
No 183/1193 17.1 1.0
Asked for ACT Yes 114/138 86.2 53.28 (15.9-179.1) <0.001 55.47 (15.0-205.6) <0.001
No 168/1382 10.6 1.0 1.0
Health facility characteristics
Type of facility Public 94/430 16.6 0.70 (0.29-1.67) 0.385
Retailer 188/1090 22.2 1.0
Weighing scale available Yes 216/892 27.2 2.13 (1.05-4.32) 0.037
No 66/628 14.6 1.0
Thermometer available Yes 198/872 27.5 1.94 (1.01-3.71) 0.046 1.99 (0.94-4.18) 0.068
No 84/648 16.2 1.0 1.0
Offer malaria microscopy Yes 17/70 24.0 1.12 (0.77-1.63) 0.519
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would be merit in further examining the role of patient
demand in influencing the choice of treatment for
uncomplicated malaria in private sector facilities.
Conclusions
ACT became the recommended treatment for uncom-
plicated malaria in 2005, though they remain underused,
and less than a quarter of febrile patients attending
health facilities in this study received ACT. Although
there is increasing emphasis on the parasitological rather
than symptomatic diagnosis of malaria, the study sug-
gests that there is a need for interventions that also
focus on choice of treatment to ensure that patients
with malaria receive the recommended anti-malarial,
irrespective of the diagnostic method. Improving the
provision of health services should also address the
quality of dispensing, and ensure that health workers
can accurately determine the correct dose across a
range of different brands and types of ACT. Concur-
rently attention needs to be given to the high availability
and use of artemisinin monotherapy, as well as the con-
tinued use of less effective treatments, particularly SP.
Consideration should also be given to the role of patient
demand in influencing the treatment received, especially
in medicine retailers, since this was found to be a major
determinant of whether patients received an ACT. Thus,
in developing interventions to improve malaria case
management the results demonstrate the importance of
addressing both demand and supply-side influences on
malaria treatment.
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